Gregory Lee

Upon completion of his PhD degree in Biophysical Chemistry at California Institute of Technology in 1972, he joined Dr. Nathan Kaplan’s lab at UCSD as NIH Postdoctoral Fellow to carry out pioneer work on general ligand affinity chromatography. In 1976, he joined National Institutes of Health as senior fellow to study enzymology and biochemical genetics. In 1981, he was appointed as faculty member and director of Andrology Laboratory at The University of British Columbia. During the last two decades, he has created numerous monoclonal antibodies for diagnostic and therapeutic applications in human health care. Among these, RP215 and GHR106 monoclonal antibodies have recently been discovered to be promising candidates of multi-indication anti-cancer drugs for the therapeutic treatments of various human cancers in the future.